PIP4K2A and acute myeloid leukemia: Compound CC260 (3), with dual activity at PI5P4Kα and PI5P4Kβ,13 reduced proliferation in p53 null cancer cell lines in the presence of stress caused by nutrient depletion, in concordance with earlier findings.12 More specifically, selective inhibition of PI5P4Kα may also have positive therapeutic effects, as demonstrated by the genetic depletion of PI5P4Kα in p53 null THP-1 cells which resulted in the inhibition of proliferation and also prevented AML development in xenografts.14